Healthcare & Life Sciences

“They grasp the client’s needs quickly and provide accurate and thorough feedback within the timex-frame. Plus, their interdepartmental collaboration is hugely helpful.”

- Chambers & Partners Asia-Pacific

Overview

BKL provides comprehensive legal services to international and domestic clients in the fields of medical service, pharmaceutical products, medical device, animal drugs, food and beverage and cosmetics and personal care products. We have experts with extensive knowledge and experience in related fields, including pharmaceutical and healthcare regulations, patents and licensing, dispute resolution, government investigations, fair trade, M&A and initial public offerings, who work closely with one another to deliver the best results for clients.

Our Healthcare & Life Sciences Group regularly advises pharmaceutical companies and medical institutions on the full spectrum of issues they face during the course of their business operations in and outside of Korea. Our practitioners are well-versed not only in the laws and regulations but also in the characteristics of the industry, and we provide strategic advice on a broad range of business initiatives and transactions such as M&A, IPO, global expansion, technology licensing and new business models in order to proactively address clients’ business objectives. We have advised clients on strategic alliances and M&A deals that are core to their business strategy, as well as on the largest cross-border out-licensing deal by a Korean pharmaceutical company as licensor.

BKL has a long history of assisting pharmaceutical companies and medical institutions in dealing with constantly evolving healthcare regulations and various compliance issues. BKL provides expert guidance on product approvals and reimbursement listing and has a proven track record of successfully representing pharmaceutical companies in complex litigations over the government’s pricing reductions and other administrative actions. The number of disputes has grown with respect to use of sensitive personal information, artificial intelligence, telemedicine and drug development, and we provide pharmaceutical companies and medical institutions with tailored advice to help them address increased regulatory complexities in the healthcare sector.

Our Healthcare & Life Sciences Group takes a multidisciplinary approach and works closely with firm experts in other related fields such as intellectual property, privacy and data protection and fair trade regulations to advise pharmaceutical companies, medical device manufacturers and other healthcare related companies and institutions on a wide range of regulatory issues such as product liability and recalls, personal information protection, advertisement and distribution practices in the industry (which may have fair trade implications) and contacts with healthcare professionals.

Key Services

Advise on regulations and compliance and provide legal representation in related disputes
Advise on intellectual property, including patent and technology licensing, and provide legal representation in related disputes
M&A, joint venture, and IPO

Representative Cases

Advised Hanmi Pharmaceutical on technology licensing agreements with Sanofi, Eli Lilly, Boehringer Ingelheim, and Janssen
Advised on the acquisition of VATECH’s mammography division by GE Healthcare
Represented 36 pharmaceutical companies in a lawsuit against the National Health Insurance Service in connection with reimbursement for Valsartan
Technology licensing
Advised Hanmi Pharmaceutical on technology licensing agreements with Sanofi, Eli Lilly, Boehringer Ingelheim, and Janssen
Advised on the acquisition of VATECH’s mammography division by GE Healthcare
Advised on the listing of SK Biopharmaceuticals, Psomagen, etc. on the KOSDAQ market of the Korea Exchange
Disputes / regulation
Represented Samsung Medical Center in a lawsuit relating to its response to MERS
Represented pharmaceutical companies in a lawsuit relating to comprehensive reduction of medicine prices by the Ministry of Health and Welfare
Represented 36 pharmaceutical companies in a lawsuit against the National Health Insurance Service in connection with reimbursement for Valsartan